Brca1 deficiency exacerbates estrogen-induced dna damage and genomic instability

Cancer Research

Volumn 74, Issue 10, 2014, Pages 2773-2784

  Savage, Kienan I ^a   Matchett, Kyle B ^a   Barros, Eliana M ^a   Cooper, Kevin M ^a   Irwin, Gareth W ^a   Gorski, Julia J ^a   Orr, Katy S ^a   Vohhodina, Jekaterina ^a   Kavanagh, Joy N ^a   Madden, Angelina F ^a   Powell, Alexander ^a   Manti, Lorenzo ^b   Mcdade, Simon S ^a   Park, Ben Ho ^c   Prise, Kevin M ^a   Mcintosh, Stuart A ^a   Salto Tellez, Manuel ^a   Richard, Derek J ^d   Elliott, Christopher T ^a   Harkin, D Paul ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 4 HYDROXYESTRADIOL; BRCA1 PROTEIN; CYTOCHROME P450 1A1; ESTROGEN; ESTROGEN RECEPTOR ALPHA;

ARTICLE; BREAST CELL; CARCINOGENESIS; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ESTROGEN METABOLISM; GENE MUTATION; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLITE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BREAST; BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A1; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; ESTRADIOL; ESTROGENS; ESTROGENS, CATECHOL; FEMALE; GENOMIC INSTABILITY; HUMANS; MCF-7 CELLS;

EID: 84901284078     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2611     Document Type: Article

References (44)

1. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010;11:138-48.
2. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM, et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011;477:179-84.
3. Pathania S, Nguyen J, Hill SJ, Scully R, Adelmant GO, Marto JA, et al. BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol Cell 2011;44:235-51.
4. Chen S, Parmigiani G. Meta-Analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
5. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-706.
6. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
7. Rebbeck TR, LynchHT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
8. Narod SA, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Neuhausen SL, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? Cancer Epidemiol Biomarkers Prev 2012;21:1089-96.
9. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999;354:1846-50.
10. Chand AL, Simpson ER, Clyne CD. Aromatase expression is increased in BRCA1 mutation carriers. BMC Cancer 2009;9:148.
11. Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, et al. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005;24:8343-8.
12. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012;21:134-47.
13. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-8.
14. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, et al. Molecular basis for estrogen receptor alpha deficiency inBRCA1-linked breast cancer. J Natl Cancer Inst 2007;99:1683-94.
15. Yue W, Wang JP, Li Y, Fan P, Liu G, Zhang N, et al. Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 2010;127:1748-57.
16. Huang J, Sun J, Chen Y, Song Y, Dong L, Zhan Q, et al. Analysis of multiplex endogenous estrogen metabolites in human urine using ultra-fast liquid chromatography-tandem mass spectrometry: a case study for breast cancer. Anal Chim Acta 2012;711:60-8.
17. Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697-702.
18. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235-7.
19. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986;24: 353-6.
20. Chakravarti D, Mailander PC, Li KM, Higginbotham S, Zhang HL, Gross ML, et al. Evidence that a burst ofDNAdepurination inSENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 2001;20:7945-53.
21. Zhao Z, Kosinska W, Khmelnitsky M, Cavalieri EL, Rogan EG, Chakravarti D, et al. Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. Chem Res Toxicol 2006;19:475-9.
22. Mailander PC, Meza JL, Higginbotham S, Chakravarti D. Induction of A.T to G.C mutations by erroneous repair of depurinatedDNAfollowing estrogen treatment of the mammary gland of ACI rats. J Steroid Biochem Mol Biol 2006;101:204-15.
23. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008;122:1949-57.
24. Gaikwad NW, Yang L, Pruthi S, Ingle JN, Sandhu N, Rogan EG, et al. Urine biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer (Auckl) 2009;3:1-8.
25. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006;1766:63-78.
26. Mizutani A, Okada T, Shibutani S, Sonoda E, Hochegger H, Nishigori C, et al. Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. Cancer Res 2004;64: 3144-7.
27. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A 2011;108:17773-8.
28. Gorski JJ, Savage KI, Mulligan JM,McDade SS, Blayney JK,GeZ, et al. Profiling of the BRCA1 transcriptome through microarray and ChIPchip analysis. Nucleic Acids Res 2011;39:9536-48.
29. Manti L, Durante M, Grossi G, Ortenzia O, Pugliese M, Scampoli P, et al. Measurements of metaphase and interphase chromosome aberrations transmitted through early cell replication rounds in human lymphocytes exposed to low-LET protons and high-LET 12C ions. Mutat Res 2006;596:151-65.
30. Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, et al. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 2005;77:6646-54.
31. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-70.
32. Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, et al. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res 2010;70: 2538-47.
33. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 2004;64:7893-909.
34. Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 2009;117:31-41.
35. Ernestos B, Nikolaos P, Koulis G, Eleni R, Konstantinos B, Alexandra G, et al. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay. Int J Radiat Oncol Biol Phys 2010;76:1199-205.
36. Suzuki N, Yasui M, Santosh Laxmi YR,Ohmori H, Hanaoka F, Shibutani S. Translesion synthesis past equine estrogen-derived 20-deoxycytidine DNA adducts by human DNA polymerases eta and kappa. Biochemistry 2004;43:11312-20.
37. Yasui M, Suzuki N, Liu X, Okamoto Y, Kim SY, Laxmi YR, et al. Mechanism of translesion synthesis past an equine estrogen-DNA adduct by Y-family DNA polymerases. J Mol Biol 2007;371:1151-62.
38. Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER. Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell 2009;20:3374-89.
39. Feng Z, Zhang J. A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest. Nucleic Acids Res 2012;40:726-38.
40. Berstein LM, Koskela A, Boyarkina MP, Adlercreutz H. Excretion of estrogens, catecholestrogensandphytoestrogens in carriers ofBRCA1 gene mutations: effects of metformin. Neoplasma 2010;57:333-8.
41. Lindgren PR, Backstrom T, Cajander S, Damber MG, Mahlck CG, Zhu D, et al. The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors. Int J Oncol 2002;21: 583-9.
42. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-6.
43. Del Mastro L, Levaggi A, Giraudi S, Pronzato P. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives. Cancer Treat Rev 2011;37:208-11.
44. Rossi E, Morabito A, De Maio E, Di Rella F, Esposito G, Gravina A, et al. Endocrine effects of adjuvant letrozole triptorelin compared with tamoxifen triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 2008;26:264-70.